Oral SAHA (Suberoylanilide Hydroxamic Acid) in Advanced Cutaneous T-cell Lymphoma (0683-001)

Sponsor
Merck Sharp & Dohme LLC
Study ID
NCT00091559
Phase
PHASE2
Status
Completed

Conditions

  • Cutaneous T-cell Lymphoma
  • Mycosis Fungoides
  • Sezary Syndrome

Eligibility Criteria

Sex
ALL
Age
18 Years - N/A
Healthy Volunteers
Not accepted

Interventions

Study Details

A study for patients diagnosed with advanced cutaneous T-cell lymphoma (stage 1B or higher) who have progressive, persistent, or recurrent disease on or following 2 other therapies, one of which must have contained Targretin (bexarotene)or for patients who are not candidates or could not tolerate Targretin therapy.

Key Dates

Start date
Feb 3, 2005
Status verified
Apr 2017
Primary completion
Nov 23, 2005
Completion
Mar 13, 2006

Study Design

Enrollment
74 participants (actual)
Allocation
NON_RANDOMIZED
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT

Primary Outcome Measure

Objective response rate in patients with progressive, persistent, or recurrent disease.

Related Studies